Saqib Nazir, MD
Internal Medicine · Milledgeville, GANPI 1649339508
Payments from drug & device makers
Across 589 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- GSK$782
- Astellas Pharma US Inc$762
- Bayer$728
- Lilly USA, LLC$685
- plus $5K from 32 others
What the payments were for
- Food & beverage$10,05597%
- Education$3033%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,353 |
| AstraZeneca | 74 | $1,322 |
| GSK | 40 | $782 |
| Astellas Pharma US Inc | 29 | $762 |
| Bayer | 37 | $728 |
| Lilly USA, LLC | 41 | $685 |
| AbbVie(2 entities) | 34 | $534 |
| Pfizer | 38 | $531 |
| Sumitomo Pharma America, Inc. | 22 | $435 |
| Merck | 22 | $361 |
| Boehringer Ingelheim | 21 | $340 |
| Sanofi-aventis U.S. LLC | 20 | $323 |
| Hikma Pharmaceuticals USA | 17 | $287 |
| Johnson & Johnson | 19 | $236 |
| Sunovion Pharmaceuticals Inc. | 10 | $158 |
| Novartis | 8 | $151 |
| Amgen | 8 | $149 |
| Eyevance Pharmaceuticals LLC | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $134 |
| Amarin Pharma, Inc. | 7 | $124 |
| Corcept Therapeutics | 3 | $82 |
| Abbott | 4 | $80 |
| Biohaven Pharmaceuticals, Inc. | 5 | $79 |
| Exact Sciences | 4 | $76 |
| Dexcom, Inc. | 4 | $72 |
| Ardelyx, Inc. | 3 | $65 |
| Biogen | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Eisai Inc. | 2 | $37 |
| Smith+Nephew | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Cequr Corporation | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Athena Bioscience, LLC | 1 | $8 |
How this compares
$10,358 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 712 | $831,836 |
| FarxigaDapagliflozin Propanediol | 496 | $454,628 |
| EliquisApixaban | 250 | $208,647 |
| JardianceEmpagliflozin | 137 | $161,134 |
| EnbrelEtanercept | 18 | $156,439 |
| TrulicityDulaglutide | 102 | $151,863 |
| MounjaroTirzepatide | 138 | $148,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $148,097 |
| LinzessLinaclotide | 147 | $129,564 |
| EntrestoSacubitril/Valsartan | 105 | $114,369 |
| KerendiaFinerenone | 98 | $92,966 |
| JanuviaSitagliptin Phosphate | 109 | $90,375 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 51 | $54,811 |
| GemtesaVibegron | 71 | $53,542 |
| XareltoRivaroxaban | 38 | $52,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,353 | $831,836712 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,322 | $506,197618 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $685 | $300,566240 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $340 | $235,745230 claims |
| PfizerEliquis | $531 | $208,647250 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $782 | $164,840236 claims |
| AmgenEnbrel | $149 | $156,43918 claims |
| AbbVieLinzess, Creon | $534 | $152,341159 claims |
| NovartisEntresto | $151 | $114,369105 claims |
| MerckJanuvia, Janumet | $361 | $102,272124 claims |
| BayerKerendia | $728 | $92,96698 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $323 | $54,81151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Milledgeville
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.